Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

UK pharma major GSK and private French biotech Syndivia company, which is focused on next-generation antibody-drug conjugate ...

Speed up your language learning with AI. This guide provides 4 expert tips for using ChatGPT to master conversation, build ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

European stocks were subdued on Friday as earnings proved to be a mixed bag and investors braced for the release of delayed U.S.

The major U.S. index futures are currently pointing to a higher open on Friday, with stocks likely to extend the upward move seen ...

London stocks opened mixed on Monday, with the FTSE 100 edging up 0.1% to 9,651.66 as the UK market lagged a broader global rally driven by optimism over a potential US-China trade deal. The FTSE 250 ...

French VC Andera Partners has reached the first close of its Biodiscovery Fund 7 at more than €300 million (US$349 million) and says it is on track to surpass the size of the previous fund, which ...

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Jennifer G. Sullivan ...